Correlation between pre-treatment serum total blood bilirubin and unconjugated bilirubin and prognosis in patients with colorectal cancer

Table 2 Relationship between total bilirubin level grouping and basic clinical characteristics of patients (mean ± SD)

		TBIL ≤ 13.45 μmol/L (n = 70)	TBIL > 13.45 μmol/L (n = 72)	t/χ2	P value
Age (yr)		65.21 ± 8.33	63.03 ± 9.73	1.437	0.153
TBIL (μmol/L)		10.65 ± 2.11	17.70 ± 4.43	12.163	< 0.001
UCB (μmol/L)		8.81 ± 2.42	13.48 ± 4.10	8.297	< 0.001
Sex	Male	49 (70.0)	42 (58.3)	2.099	0.147
	Female	21 (30.0)	30 (41.7)
Grade	High	20 (18.6)	26 (36.1)	16.039	< 0.001
	Middle	16 (22.9)	33 (45.8)
	Low	34 (48.6)	13 (18.1)
Diameter	< 5 cm	26 (37.1)	38 (52.8)	3.505	0.061
	≥ 5 cm	44 (62.9)	34 (47.2)
Site	Rectum	26 (37.1)	34 (47.2)	1.508	0.471
	Right	20 (28.6)	18 (25.0)
	Left	24 (34.3)	20 (27.8)
Lymph node metastasis	No	27 (38.6)	40 (55.6)	4.108	0.043
	Yes	43 (61.4)	32 (44.4)
TNM	Ⅰ	23 (32.9)	34 (47.2)	6.077	0.048
	Ⅱ	22 (31.4)	25 (34.7)
	Ⅲ	25 (35.7)	13 (18.1)
Smoking	Yes	23 (32.9)	26 (36.1)	0.166	0.683
	No	47 (67.1)	46 (63.9)
Chemotherapy	Yes	42 (60.0)	38 (52.8)	0.753	0.386
	No	28 (40.0)	34 (47.2)

T-test for age, total bilirubin, unconjugated bilirubin, χ² for gender, degree of tumour differentiation, tumour diameter, tumour location, presence of lymph node metastasis, pathological tumour, node, and metastasis stage, smoking, whether chemotherapy. TBIL: Total bilirubin; UCB: Unconjugated bilirubin; TNM: Tumor, node, and metastasis.